skip to content National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Skip to subnavigation.
Programs & Resources
skip sub-navigation, go to content.

Prostate and Urologic Cancer Research Group

Publications and Presentations


2008 Publications

Faupel-Badger J, Kidd LR, Albanes D, Virtamo J, Woodson K, Tangrea JA. Association of interleukin-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control, 2008; 19(2): 119-124.

Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 1;14(1):224-9.

Song Y, Tangen C, Goodman P, Parnes HL, Lucia MS, Thompson IM, Kristal AR. Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. Prostate. 2008 Feb 15;68(3):281-6.

2007 Publications

Faupel-Badger J, Diaw L, Albanes D, Virtamo J,Woodson K, Tangrea JA. Lack of association between serum levels of 25-hydroxyvitamin D and subsequent risk of prostate cancer in Finnish men. Cancer Epidemiol Biomarkers Prev, 2007; 16(12): 2784-6.

Hoque A, Parnes HL, Stefanek ME, Heymach JV, Brown PH, Lippman SM. Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. Cancer Res. 2007 Oct 1;67(19):8989-93.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83.

Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, Feldman J, Poole DJ, Litzinger M, Steinberg SM, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley JL. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol. 2007 Oct;178(4 Pt 1):1515-20.

Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A; Workshop Program Committee. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007;3(1):1-33.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol. 2007 Jul 20;25(21):3076-81.

Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol. 2007 Jul;178(1):107-9; discussion 110.

Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA Jr. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol. 2007 May;177(5):1749-52.

Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007 May;99(5):1047-55.

2006 Publications

Gulley JL, Parnes HL, Wright J, Dahut WL. Early treatment gets the benefit. J Clin Oncol. 2006 Nov 10;24(32):5172-3; author reply 5173.

Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst, 2006, 98: 255-61.

Parnes HL, Figg WD. Chemoprevention in prostate cancer. Pharmacotherapy. 2006 Oct;26(10):1533; author reply 1533.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.

Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006 Aug;176(2):500-4.

Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK; AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res. 2006 Jun 15;12(12):3661-97.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.J Natl Cancer Inst. 2006 Apr 19;98(8):529-34.

Yang HP, Woodson K, Taylor PR, Pietinen P, Albanes D, Virtamo J, Tangrea JA. Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. European J Cancer Prev, 2006, 15: 249-53.

Book Chapters

Tangrea JA, House MG, Parnes HL. Prostate Cancer Epidemiology and Prevention. In: Prostate Cancer: A Clinical Guide. Prostate Cancer Foundation, New York: Lippincott, 2008.